IP Library Granted Patent US 12,188,083
Granted Patent B2
US 12,188,083 · App. 16/428,735 · Granted Jan 7, 2025

Products and processes for nucleic acid detection and quantification

Inventor: Michael Mosko (Poway, CA)
Assignee: AGENA BIOSCIENCE, INC.
C12Q1/6827C12Q1/6813C12Q2600/156
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,188,083
App. No.
16/428,735
Granted
Jan 7, 2025
Kind
B2
Abstract

Provided herein are products and processes for primer extension reactions using chain terminating reagents and enzymes having 3′ to 5′ exonuclease activity, whereby unextended oligonucleotides are digested and extended oligonucleotides are not digested. Also provided herein are products and processes for the detection of the presence, absence or amount of one or more variants of a target nucleic acid species or a plurality of target nucleic acid species comprising primer extension reactions using chain terminating reagents and enzymes having 3′ to 5′ exonuclease activity, whereby unextended oligonucleotides are digested and extended oligonucleotides are not digested.

Claims (50)

1. A method for detecting the presence, absence or amount of variants of one or more target nucleic acid species or amplicons thereof, comprising:

(a) contacting a sample comprising one or more target nucleic acid species or amplicons thereof with one or more primer oligonucleotides, wherein each primer oligonucleotide comprises a region that corresponds to a portion of a target nucleic acid species or amplicon thereof and wherein each of the one or more target nucleic acid species or amplicon thereof (1) comprises at least two variants and (2) each of the one or more primer oligonucleotides is specific for a target nucleic acid species or amplicon thereof and is capable of hybridizing to the variants of the target nucleic acid species or amplicon thereof at a position 5′ to a single base position that differs between each of the variants of the target nucleic acid species or amplicon thereof, thereby generating hybridized oligonucleotides;

(b) contacting the hybridized oligonucleotides with an extension composition comprising one or more chain terminating reagents each specific for a variant of a target nucleic acid species or amplicon thereof under extension conditions, wherein the hybridized primer oligonucleotides are each extended up to, or through, the nucleotide position that is different between the variants of a corresponding target nucleic acid species or amplicon thereof, thereby generating extended primer oligonucleotides that each comprise a chain terminating reagent specific for one or more variants of the corresponding target nucleic acid species or amplicon thereof;

(c) contacting the products of (b) with an enzyme having 3′ to 5′ exonuclease activity, whereby unextended primer oligonucleotides are digested and extended primer oligonucleotides comprising a chain terminating reagent are not digested; and

(d) without subjecting the products of (b) or the products of (c) to selective capture of the extended primer oligonucleotides from the mixture of extended primer oligonucleotides and unextended primer oligonucleotides in (b) or (c), analyzing detecting the presence, absence or amount of the extended primer oligonucleotides, thereby detecting the presence, absence or amount of variants of the one or more target nucleic acid species or amplicons thereof in the sample.

2. The method of claim 1 , wherein at least one chain terminating reagent, when incorporated into a primer oligonucleotide in (b), blocks the 3′ to 5′ exonuclease activity of the enzyme.

3. The method of claim 2 , wherein at least one chain terminating reagent is a chain terminating nucleotide or all of the one or more chain terminating reagent(s) is/are a chain terminating nucleotide.

4. The method of claim 3 , wherein the chain terminating reagent(s) is/are a dideoxynucleotide or an acyclic nucleotide.

5. The method of claim 4 , wherein the dideoxynucleotide is selected from among ddATP, ddGTP, ddCTP, ddTTP and ddUTP and the acyclic nucleotide is selected from among acyATP, acyCTP, acyGTP, acyTTP and acy-Bromo-UTP.

6. The method of claim 1 , wherein the extension composition comprises two, three or four chain terminating reagents in equimolar concentrations.

7. The method of claim 1 , wherein:

(1) each of the one or more target nucleic acid species or amplicons thereof comprises a low-abundance variant and a high-abundance variant;

(2) each of the one or more primer oligonucleotides of (a) is specific for a target nucleic acid species or amplicon thereof and hybridizes to both the low-abundance variant and the high-abundance variant of the target nucleic acid species or amplicon thereof at a position 5′ to a single base position that differs between the low-abundance variant and the high-abundance variant of the target nucleic acid species, thereby generating hybridized oligonucleotides;

(3) in (b), the hybridized oligonucleotides of (2) are contacted with an extension composition comprising a chain terminating reagent specific for the low-abundance variants under extension conditions; wherein the primer oligonucleotides that hybridize to the low-abundance variant are extended by the chain terminating reagent, thereby generating extended oligonucleotides, and the primer oligonucleotides that hybridize to the high-abundance variant are not extended;

(4) in (c), the products of (3) are contacted with the enzyme having 3′ to 5′ exonuclease activity, whereby the unextended primer oligonucleotides are digested and the extended primer oligonucleotides are not digested; and

(5) in (d), the presence, absence or amount of the extended primer oligonucleotides of (4) is detected, thereby detecting the presence, absence or amount of variants of the target nucleic acid species or amplicons thereof.

8. The method of claim 1 , wherein:

(1) the sample comprises a plurality of target nucleic acid species or amplicons thereof, wherein each target nucleic acid species or amplicon thereof has a low-abundance variant and a high-abundance variant;

(2) the nucleic acids of (a) are hybridized with a plurality of primer oligonucleotides, and each primer oligonucleotide is specific for a target nucleic acid species or amplicon thereof and hybridizes to both the low-abundance variant and the high-abundance variant of the target nucleic acid species or amplicon thereof at a position 5′ to a single base position that differs between the low-abundance variant and the high-abundance variant of the target nucleic acid species, thereby generating hybridized oligonucleotides, wherein:

(i) the nucleotide at the single base position is the same or different for each of the high-abundance variants of the plurality of target nucleic acid species,

(ii) the nucleotide at the single base position is the same for each of the low-abundance variants of the plurality of target nucleic acid species, and

(iii) none of the nucleotides at the single base position for the high-abundance variants of the plurality of target nucleic acid species is the same as the nucleotide at the single base position for the low-abundance variants of the target nucleic acid species,

(3) in (b), the hybridized oligonucleotides of (2) are contacted with an extension composition comprising a chain terminating reagent specific for the low-abundance variants and one, two or three chain terminating reagents specific for one or more of the high-abundance variants under extension conditions, wherein:

(i) the one, two or three chain terminating reagents specific for one or more high-abundance variants are each at a concentration less than the concentration of the chain terminating reagent specific for the low-abundance variants, and

(ii) the extension conditions comprise multiple thermal cycles, thereby generating extended primer oligonucleotides comprising a chain terminating reagent specific for the low-abundance variants of the plurality of target nucleic acid species and/or extended primer oligonucleotides comprising a chain terminating reagent specific for the high-abundance variants of the target nucleic acid species;

(4) in (c), the products of (3) are contacted with the enzyme having 3′ to 5′ exonuclease activity, whereby the unextended primer oligonucleotides are digested and the extended primer oligonucleotides comprising a chain terminating reagent are not digested; and

(5) in (d), the presence, absence or amount of the extended primer oligonucleotides of (4) is detected, thereby detecting the presence, absence or amount of variants of the target nucleic acid species or amplicons thereof.

9. The method of claim 1 , wherein a plurality of target nucleic acid species or amplicons thereof are detected in a single, multiplexed reaction.

10. The method of claim 1 , wherein the enzyme is TTHB178.

11. The method of claim 1 , wherein the primer oligonucleotides hybridized with the target nucleic acid species or amplicons thereof do not include a detectable label attached thereto and the chain terminating reagent(s) do not include a detectable label attached thereto.

12. The method of claim 1 , wherein (d) does not include detection of a detectable label attached to the primer oligonucleotide(s) that are extended or attached to a chain terminating reagent.

13. The method of claim 1 , wherein the extended primer oligonucleotides are analyzed by mass spectrometry.

14. The method of claim 1 , wherein:

(1) the one or more target nucleic acids comprises a plurality of target nucleic acid species or amplicons thereof, wherein each species or amplicon thereof has a low-abundance variant and a high-abundance variant;

(2) the target nucleic acid species or amplicons thereof of (a) are hybridized with a plurality of primer oligonucleotides, and each primer oligonucleotide is specific for a target nucleic acid species or amplicon thereof and hybridizes to both the low-abundance variant and the high-abundance variant of the target nucleic acid species or amplicon thereof at a position 5′ to a single base position that differs between the low-abundance variant and the high-abundance variant of the target nucleic acid species, thereby generating hybridized oligonucleotides, wherein:

(i) the nucleotide at the single base position is the same for each of the high-abundance variants of the plurality of target nucleic acid species,

(ii) the nucleotide at the single base position is the same or different for each of the low-abundance variants of the plurality of target nucleic acid species, and

(iii) none of the nucleotides at the single base position for the low-abundance variants of the plurality of target nucleic acid species is the same as the nucleotide at the single base position for the high-abundance variants of the target nucleic acid species;

(3) in (b), the hybridized oligonucleotides of (2) are contacted with an extension composition comprising a chain terminating reagent specific for the high-abundance variants and one or more chain terminating reagents specific for one or more of the low-abundance variants under extension conditions, thereby generating extended primer oligonucleotides comprising a chain terminating reagent specific for the low-abundance variants of the plurality of target nucleic acid species and/or extended primer oligonucleotides comprising a chain terminating reagent specific for the high-abundance variants of the target nucleic acid species wherein:

(i) the high-abundance variants share a common chain terminating reagent that is specific for the high-abundance variants and is not specific for the low-abundance variants,

(ii) each of the low-abundance variants has a chain terminating reagent that is specific for the low-abundance variant and is not specific for the high-abundance variant, wherein the chain terminating reagent that is specific for the low-abundance variant either: (A) is unique for a particular low-abundance variant in the composition and is not shared by the other low-abundance variants in the composition, or (B) at least one of the low-abundance variants share a common chain terminating reagent with at least one other low-abundance variant in the composition, and

(iii) the concentration of the chain terminating reagent specific for the high-abundance variants is less than the concentration of the chain terminating reagent(s) specific for the low-abundance variants;

(4) in (c), the products of (3) are contacted with the enzyme having 3′ to 5′ exonuclease activity, whereby the unextended primer oligonucleotides are digested and the extended primer oligonucleotides comprising a chain terminating reagent are not digested; and

(5) in (d), the presence, absence or amount of the extended primer oligonucleotides of (4) is detected, thereby detecting the presence, absence or amount of variants of the target nucleic acid species or amplicons thereof.

15. The method of claim 1 , wherein the target nucleic acid species or amplicons thereof, the one or more primer oligonucleotides, the products of (b) and the products of (c) are not captured by binding to a solid phase.

16. The method of claim 1 , wherein the target nucleic acid species or amplicons thereof, primer oligonucleotides, extended primer oligonucleotides and chain terminating reagents do not comprise a capture agent or member of a binding pair for which the other member of the binding pair is linked to a solid phase.

17. The method of claim 1 , wherein the target nucleic acid species or amplicons thereof of the sample are hybridized in (a) to a plurality of primer oligonucleotides each comprising a region that corresponds to a portion of one of a plurality of target nucleic acids.

18. The method of claim 7 , wherein the target nucleic acid species or amplicons thereof, the one or more primer oligonucleotides, the products of (3) and the products of (4) are not captured by binding to a solid phase.

19. The method of claim 8 , wherein the target nucleic acid species or amplicons thereof, the plurality of primer oligonucleotides, the products of (3) and the products of (4) are not captured by binding to a solid phase.

20. The method of claim 14 , wherein the plurality of primer oligonucleotides, the products of (3) and the products of (4) are not captured by binding to a solid phase.

Assignments (2)
SECURITY INTEREST Recorded Dec 10, 2021
From: AGENA BIOSCIENCE, INC.
To: JPMORGAN CHASE BANK, N.A.
Reel/Frame 058358/0661 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 3, 2019
From: MOSKO, MICHAEL
To: AGENA BIOSCIENCE, INC.
Reel/Frame 049348/0547 →
Continuity (2)
Provisional Application 62679450 · Jun 1, 2018
Related Publication 20190367970A1 · Dec 5, 2019
References Cited (55)
US 5547835A · Koester · 1996 [cited by applicant]
US 6043031A · Koester et al. · 2000 [cited by applicant]
US 8003317B2 · Beaulieu et al. · 2011 [cited by applicant]
US 8349566B2 · Beaulieu et al. · 2013 [cited by applicant]
US 9068223B2 · Beaulieu et al. · 2015 [cited by applicant]
US 9896724B2 · Beaulieu et al. · 2018 [cited by applicant]
US 10233489B2 · Nygren · 2019 [cited by applicant]
US 10513728B2 · Nygren · 2019 [cited by applicant]
US 10604791B2 · Honisch et al. · 2020 [cited by applicant]
US 10640817B2 · Nygren · 2020 [cited by examiner]
US 10865439B2 · Nygren · 2020 [cited by applicant]
US 20020177141A1 · Chee · 2002 [cited by examiner]
US 20030186234A1 · Kurn · 2003 [cited by examiner]
US 20050181394A1 · Steemers · 2005 [cited by examiner]
US 20050287533A1 · Ehrich et al. · 2005 [cited by applicant]
US 20050287592A1 · Kless · 2005 [cited by applicant]
US 20070122811A1 · Buzby · 2007 [cited by applicant]
US 20080242555A1 · Shen et al. · 2008 [cited by applicant]
US 20120028826A1 · Fu et al. · 2012 [cited by applicant]
US 20120046178A1 · Van Den Boom et al. · 2012 [cited by applicant]
US 20140011195A1 · Honisch et al. · 2014 [cited by applicant]
US 20140242577A1 · Peter · 2014 [cited by examiner]
US 20170058335A1 · Tao · 2017 [cited by examiner]
US 20170247756A1 · Schreiber et al. · 2017 [cited by applicant]
US 20180245146A1 · Beaulieu et al. · 2018 [cited by applicant]
US 20200318169A1 · Honisch et al. · 2020 [cited by applicant]
US 20210062254A1 · Nygren · 2021 [cited by applicant]
CN 1461349A · 2003 [cited by applicant]
CN 1620515A · 2005 [cited by applicant]
CN 102203287A · 2011 [cited by applicant]
CN 103717751A · 2014 [cited by applicant]
CN 103917660A · 2014 [cited by applicant]
CN 105980579A · 2016 [cited by applicant]
EP 3382034A1 · 2018 [cited by applicant]
WO 9737041A2 · 1997 [cited by applicant]
WO 02083949A1 · 2002 [cited by applicant]
WO 03052115A2 · 2003 [cited by applicant]
WO 2005012578A1 · 2005 [cited by applicant]
WO 2010056513A2 · 2010 [cited by applicant]
WO 2012159060A2 · 2012 [cited by applicant]
WO 2012159089A1 · 2012 [cited by applicant]
WO 2016172571A1 · 2016 [cited by applicant]
WO 2016172579A1 · 2016 [cited by applicant]
WO 2019232460A1 · 2019 [cited by applicant]
Shimada et al. (Nucleic acids Research 2010 vol 38 p. 5692) (Year: 2010). [cited by examiner]
Conserved Hypothetical Protein (Plasmid) [Thermus Thermophilus HB8], GenBank Accession No. BAD71974.1, Oct. 7, 2016, 2 pages. [cited by applicant]
International Search Report and Written Opinion mailed on Aug. 21, 2019 in International Patent Application No. PCT/US2019/035031, filed on May 31, 2019, 12 pages. [cited by applicant]
Auer et al., “Synthesis and Biological Applications of 2′,3′-Dideoxynucleoside-5′-O-(α-thio) Triphosphates”, Nucleosides & Nucleotides, 1989, 8(5&6):849-853. [cited by applicant]
Mosko et al., “Ultrasensitive Detection of Multiplexed Somatic Mutations Using MALDI-TOF Mass Spectrometry”, The Journal of Molecular Diagnostics, 2016, 18(1):23-31. [cited by applicant]
Pierce et al., “Comparison of the GenMark Diagnostics eSensor Respiratory Viral Panel to Real-Time PCR for Detection of Respiratory Viruses in Children”, Journal of Clinical Microbiology, Nov. 2012, 50(11):3458-3465. [cited by applicant]
Sakata et al., “Synthesis and Properties of Novel Acyclic Nucleotides”, Article in Nucleic Acids Symposium Series, Feb. 2000, 44:47-48. [cited by applicant]
Shimada et al., “A Novel Single-Stranded DNA-Specific 3′-5′ Exonuclease, Thermus Thermophilus Exonuclease I, Is Involved in Several DNA Repair Pathways”, Nucleic Acids Research, May 2010, 38(17):5692-5705. [cited by applicant]
International Preliminary Report on Patentability Received dated Dec. 10, 2020 in International Patent Application No. PCT/US2019/035031, filed on May 31, 2019 and Published as WO 2019/232460 on Dec. 5, 2019, 8 pages. [cited by applicant]
Zhang, et al., “New Progress in Fluorescent Probe Research”, Progress in Bioengineering, vol. 20, Issue 2, Apr. 25, 2000, pp. 14-15. (With English Abstract Only). [cited by applicant]
Zhong, et al., “Construction of Electrochemical Sensor for Breast Cancer Cells Based on Nucleic Acid Degradation Catalyzed by Exonuclease I”, Analytical Chemistry, vol. 42, Issue 007, Dec. 31, 2014, pp. 1049-1052. (With… [cited by applicant]
Cited By (1)
US 12,518,859